ADCT: ASH data show strong ZYNLONTA responses across lymphoma settings, with LOTIS-5 PFS benefit

What happened

ASH presentations reported high response rates for ZYNLONTA plus glofitamab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and fixed-duration ZYNLONTA in relapsed or refractory marginal zone lymphoma (MZL). In LOTIS-5, ZYNLONTA improved progression-free survival versus R-GemOx, but overall survival showed no significant difference.

Confirmed

Global impact / market context

The reported progression-free survival benefit could support ZYNLONTA’s clinical and commercial case in the studied lymphoma setting, potentially influencing treatment uptake and revenue. However, the lack of a significant overall-survival difference means the evidence does not show patients lived longer overall.

Analyst inference

The presentations provide clinical evidence for ZYNLONTA across two lymphoma settings, but the summary gives no response-rate figures, trial population details, regulatory decisions, or sales data. Investors therefore cannot determine the size of any commercial opportunity or how findings compare with alternatives.

Analyst inference

What to watch

1. Further LOTIS-5 results and details on the progression-free survival improvement could clarify how large and durable the benefit was compared with R-GemOx. Analyst inference
2. Additional study data on ZYNLONTA combinations and fixed-duration treatment could show whether the reported responses translate into sustained benefit for patients. Analyst inference
3. Any regulatory decisions or commercial updates tied to these findings could affect access to treatment and expectations for ZYNLONTA revenue. Analyst inference

Evidence

• Original source link unavailable